Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey - 17/03/21

Doi : 10.1016/j.rmed.2021.106341

Andrea Lombardi ^a,^d,^{^{1
These authors contributed equally to this work.},}^⁎ , Marta Colaneri ^b,^{^{1
These authors contributed equally to this work.}}, Margherita Sambo ^b, Angela Di Matteo ^b, Paolo Sacchi ^b, Massimiliano Fabbiani ^c, Luigi Codecasa ^e, Stefano Aliberti ^d,^f, Francesco Blasi ^d,^f, Alessandra Bandera ^a,^d,^h, Raffaele Bruno ^b,^g, Andrea Gori ^a,^d,^h
^a Infectious Diseases Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy
^b Infectious Diseases I Unit, IRCCS San Matteo, Pavia, Italy
^c Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
^d Departement of Pathophysiology and Transplantation, University of Milano, Milano, Italy
^e TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy
^f Respiratory Unit and Cystic Fibrosis Adult Center, University of Milano, Milano, Italy
^g Department of Medical, Surgical, Diagnostic and Paediatric Science, University of Pavia, Pavia, Italy
^h Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy

^∗Corresponding author. Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy.Infectious Diseases UnitFondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoVia Francesco Sforza 35Milan20122Italy

Abstract

The disease burden due to nontuberculous mycobacteria is growing worldwide, consequently to improved diagnostic abilities and an increase in the individuals at risk. Uncertainties exist about the right moment on which start treatment. We investigated the clinical features associated with starting an antimicrobial treatment in patients with nontuberculous mycobacterial lung disease among Italian physicians involved in the field. We found that in real life predictors of starting antimicrobial treatment are quite adherent to international guidelines, with some uncertainties regarding the implication of immunosuppressive drugs.

Le texte complet de cet article est disponible en PDF.

Highlights

•	Predictors of treatment start for NTM-LD in real life are quite adherent to guideline.
•	Due to rarity physicians rarely encounter this disease in daily practice.
•	Uncertainties exist about the impact of immunosuppressive drugs.

Le texte complet de cet article est disponible en PDF.

Keywords : Nontuberculous mycobacteria, Antimycobacterial treatment, Lung disease, Clinical management

Plan

CRediT authorship contribution statement

Export

Vol 179

Article 106341- avril 2021 Retour au numéro

Article précédent

Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension – A review of the past, present and future
Beate Stubbe, Christian F. Opitz, Michael Halank, Dirk Habedank, Ralf Ewert

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey - 17/03/21

Abstract

Highlights

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL